 |
 |
 |
|
 |
articles < press << main |
 |
 |
|
|
|
|
|
|
|
| date | | | | title / topic / summary | sort by topic |
|---|
|
| 07/28/2004 | | | | Nymox Releases Further Positive Data on U.S. Clinical Trials of NX-1207 in Men with
topic: R&D: BPH (enlarged prostate) Treatments
July 28, 2004: Nymox Pharmaceutical Corporation today
released further new data from Phase 1-2 U.S. clinical trials of NX-1207, the Company's investigational new drug for benign prostatic hyperplasia (BPH). At one month, the subjects treated with NX-1207 showed a statistically significant overall mean symptom improvement of 6.87 points in BPH symptom score rating scales compared to 0.5 for controls.
(p=.0352). |
| 07/27/2004 | | | | Statin Drugs Attract Wide Attention For Alzheimer's Prevention
topic: Statins and Alzheimer's Disease
July 27, 2004: Growing attention has been given to the findings of recent
studies which have shown that the use of statin drugs is associated with dramatic reduction in the incidence of Alzheimer's Disease (AD). Nymox holds U.S. and global patent rights for the use of statin drugs for the
prevention and treatment of AD. |
| 07/20/2004 | | | | Clinical Study Shows New Use for Nymox AlzheimAlert™ Test
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
July 20, 2004: Nymox Pharmaceutical Corporation announced
today that a newly completed clinical study has shown that the Company's AlzheimAlert™ urine test has new clinical utility in the assessment of patients with symptoms of dementia. The study found in cases with confirmed cerebral vascular abnormalities associated with the mental symptoms that the AlzheimAlert™ test values
were significantly lower than in cases of Alzheimer's Disease (AD). |
| 07/14/2004 | | | | New Drug Trial Protocol Approved for Nymox Prostate Drug
topic: R&D: BPH (enlarged prostate) Treatments
July 14, 2004: Nymox Pharmaceutical Corporation announced today that the
new clinical trial protocol for the Company's investigational new drug NX-1207 for benign prostatic hyperplasia has been found acceptable by the FDA. |
| 07/13/2004 | | | | Nymox Rated “Bullish” by Standard & Poor's Stock Reports
topic: Financial
July 13, 2004: Nymox Pharmaceutical Corporation has received positive coverage in a new Standard & Poor's Stock Report. |
| 07/02/2004 | | | | Nymox Pursuing New Approaches to Fighting Alzheimer's Disease
topic: R&D: Alzheimer's Disease Treatments
July 2, 2004: Nymox Pharmaceutical Corporation is
pursuing innovative new strategies to develop treatments for Alzheimer's disease according
to Dr. Michael Munzar, the Company's Medical Director. |
| 06/30/2004 | | | | Nymox's Tobacco Exposure Products Pass the Test in Australia
topic: Tobacco Exposure Tests
June 30, 2004: Nymox Pharmaceutical Corporation announced
today that its tobacco exposure tests have been recently featured in the Australian media
as reporters put the products to the test as part of the ongoing debate in Australia over
tobacco smoking in pubs, restaurants and other public places. |
| 06/29/2004 | | | | Nymox AD Protein Marker Linked to New Cell Death Mechanism in Alzheimer's Disease
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
June 29, 2004: Nymox Pharmaceutical Corporation announced today that a new study published in the Journal of Alzheimer's Disease (J
Alzheimers Dis. June, 2004; 6(3):231-42) has reported finding important new evidence linking neural thread protein (NTP), the brain protein measured by the company's
proprietary urine AlzheimAlert™ test, to impaired insulin functioning and accelerated
death in brain cells. |
| 06/24/2004 | | | | Nymox Releases Positive Data on U.S. Clinical Trials of NX-1207 in Men with Benign Prostatic Hyperplasia -BPH-
topic: R&D: BPH (enlarged prostate) Treatments
June 24, 2004: Nymox Pharmaceutical Corporation today newly released data from Phase 1-2 U.S. clinical trials of NX-1207, the Company's investigational new drug for benign prostatic hyperplasia (BPH). |
| 06/03/2004 | | | | Nymox Gives Update Before Company's Annual General Meeting
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
June 3, 2004: Nymox Pharmaceutical Corporation
announced today that the Company's Premarket Approval application (PMA) for its Urine NTP
Test will be going before an FDA panel meeting. |
|